Table 1. gB-specific antibody responses in rabbits immunized with Vaxfectin^®-formulated monovalent and bivalent vaccines^a.

Study A: Monovalent Vaccine					Study B: Bivalent Vaccine
Total DNA	VR-6365	GMT (Range)	Fold incr ease		Total DNA	VR-6365	GMT (Range)	Fold incr ease
0.1 mg	0.1 mg	243,550 (102,400–409,600)	-		0.1 mg	0.05 mg	332,699 (51,200–819,200)	-
1 mg	1 mg	1,502,419* (409,600–3,276,800)	6x		1 mg	0.5 mg	1,199,379* (409,600–3,276,800)	4x

^a Study A: Monovalent Vaccine, MV formulations: On Day 0 and 21, rabbits (n = 8 per group) were vaccinated either with 0.1 mg or 1 mg dose of Vaxfectin^®-formulated VR-6365 injected IM (single injection, 1 mL per muscle) using needle and syringe. Study B: Bivalent Vaccine, MV formulations: On Day 0 and 21, rabbits (n = 20 per group) received a total dose of either 0.1 mg or 1 mg of Vaxfectin^®-formulated vaccine consisting of 1:1 mass ratio of plasmids VR-6365 and VR-6368 administered IM with Biojector^® 2000. Day 42 serum samples were assayed for gB-specific antibody responses using ELISA. Geometric mean titers (GMT) and the range of titers for each group are shown. *Significantly different from group which received 0.1 mg dose of vaccine (p < 0.01).